Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Wild

Showing results (91-100 of 128) with videos related to

Pageof 13
Sort By:
Antimicrobial Agents and Chemotherapy|October 21, 2015
Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation InhibitorsEmiko Urano, Sherimay D Ablan, Rebecca Mandt, et al.
Journal of Wound Care|June 8, 2011
Clinical efficacy of a new monofilament fibre-containing wound debridement productS Bahr, N Mustafi, P Hättig, et al.
Practical Radiation Oncology|March 29, 2014
A Phase 2 Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable, Locally Advanced Pancreatic AdenocarcinomaA T Wild, D T Chang, K A Goodman, et al.
Physician Leadership Journal|July 28, 2015
IMPROVING SAFE PATIENT THROUGHPUT IN A MULTIDISCIPLINARY ONCOLOGY CLINICShereef M Elnahal, Shereef M Elnhal, Shalini Moningi, et al.
Journal of Medicinal Chemistry|June 23, 2020
Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT<sub>2C</sub> Receptor-Positive Allosteric Modulators with Enhanced Drug-like PropertiesEric A Wold, Erik J Garcia, Christopher T Wild, et al.
International Journal of Molecular Sciences|July 19, 2013
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancerSara Alcorn, Amanda J Walker, Nishant Gandhi, et al.
Virology|August 26, 2006
Determinants of activity of the HIV-1 maturation inhibitor PA-457Feng Li, Dorian Zoumplis, Claudia Matallana, et al.
Current Molecular Medicine|February 2, 2012
Tissue biomarkers for prostate cancer radiation therapyP T Tran, R K Hales, J Zeng, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2003
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processingF Li, R Goila-Gaur, K Salzwedel, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|April 2, 2013
Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: a dosimetric analysisRachit Kumar, Aaron T Wild, Mark A Ziegler, et al.
Pageof 13

Showing results (91-100 of 128) with videos related to

Sort By:
Pageof 13
Antimicrobial Agents and Chemotherapy|October 21, 2015
Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation InhibitorsEmiko Urano, Sherimay D Ablan, Rebecca Mandt, et al.
Journal of Wound Care|June 8, 2011
Clinical efficacy of a new monofilament fibre-containing wound debridement productS Bahr, N Mustafi, P Hättig, et al.
Practical Radiation Oncology|March 29, 2014
A Phase 2 Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable, Locally Advanced Pancreatic AdenocarcinomaA T Wild, D T Chang, K A Goodman, et al.
Physician Leadership Journal|July 28, 2015
IMPROVING SAFE PATIENT THROUGHPUT IN A MULTIDISCIPLINARY ONCOLOGY CLINICShereef M Elnahal, Shereef M Elnhal, Shalini Moningi, et al.
Journal of Medicinal Chemistry|June 23, 2020
Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT<sub>2C</sub> Receptor-Positive Allosteric Modulators with Enhanced Drug-like PropertiesEric A Wold, Erik J Garcia, Christopher T Wild, et al.
International Journal of Molecular Sciences|July 19, 2013
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancerSara Alcorn, Amanda J Walker, Nishant Gandhi, et al.
Virology|August 26, 2006
Determinants of activity of the HIV-1 maturation inhibitor PA-457Feng Li, Dorian Zoumplis, Claudia Matallana, et al.
Current Molecular Medicine|February 2, 2012
Tissue biomarkers for prostate cancer radiation therapyP T Tran, R K Hales, J Zeng, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2003
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processingF Li, R Goila-Gaur, K Salzwedel, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|April 2, 2013
Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: a dosimetric analysisRachit Kumar, Aaron T Wild, Mark A Ziegler, et al.
Pageof 13